The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups*

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Medical Research and Opinion

• Publication date

  2007-07-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/030079907X219526PMID 17651539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

  2006cited by this paper
• A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

  2006cited by this paper
• Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Analysis and Recommendations for Agency Action Regarding Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk

  2005cited by this paper
• VIOXX ® ( rofecoxib tablets and oral suspension )

  2003cited by this paper
• A Comparison of Adverse Renovascular Experiences Among Osteoarthritis Patients Treated with Rofecoxib and Comparator Non-selective Non-steroidal Anti-inflammatory Agents

  2002cited by this paper
• A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer.

  2002cited by this paper
• AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

  2001cited by this paper
• AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

  2001cited by this paper
• Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.

  2000cited by this paper
• Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.

  2000cited by this paper
• Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma

  2000cited by this paper
• A guideline for the treatment and prevention of NSAID-induced ulcers

  1998cited by this paper
• Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2

  1997cited by this paper
• From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.

  1997cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper

• Non-clinical cardiovascular safety testing: Current status, gaps and emerging trends.

  2025cites this paper
• Inferring Drug Set and Identifying the Mechanism of Drugs for PC3

  2024cites this paper
• An appraisal of genetic testing for prostate cancer susceptibility

  2022cites this paper
• The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers

  2022cites this paper
• Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

  2022cites this paper
• Thromboelastography as an instrument of preclinical studies of the potential drug

  2020cites this paper
• Prävention in der Uroonkologie

  2019cites this paper
• Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis

  2019cites this paper
• Non‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis

  2017cites this paper
• Complementary and Alternative Medicine and Lifestyle Changes and Prostate Cancer

  2014cites this paper
• Risk adapted chemoprevention for prostate cancer: an option?

  2014cites this paper
• Chemoprevention of prostate cancer.

  2014cites this paper
• Prevention of Prostate Cancer

  2014cites this paper
• Thromboembolic Injury Current Practices in Preclinical Drug Development : Gaps in Hemostasis Testing to Assess Risk of

  2013cites this paper
• Current Practices in Preclinical Drug Development

  2013cites this paper
• Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.

  2013cites this paper
• Entzündungshemmende Medikamente und Prostatakarzinom: Aktueller Stand der Evidenz

  2012cites this paper
• Chemoprävention des Prostatakarzinoms – Ein Plädoyer

  2012cites this paper
• Relevance of Network Hierarchy in Cancer Drug-Target Selection

  2012cites this paper
• Entzündungshemmende Medikamente und Prostatakarzinom: Aktueller Stand der Evidenz

  2012cites this paper
• Statin Clinical Trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement.

  2011cites this paper
• 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

  2011cites this paper
• Rofecoxib does not appear to increase the risk of venous thromboembolism: a systematic review of the literature.

  2011cites this paper
• Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

  2009cites this paper
• Tumor Detection by Biological Markers

  2009cites this paper
• Prostate Cancer 2008: Challenges in Diagnosis and Management

  2009cites this paper
• Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis

  2009cites this paper
• Inflammatory cytokines induce ubiquitination and loss of the prostate suppressor protein NKX3.1

  2008cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper
• Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1.

  2008influential citation
• Non‐steroidal anti‐inflammatory drugs and cardiac failure: meta‐analyses of observational studies and randomised controlled trials

  2008cites this paper
• Grundlagen der Prävention

  2007cites this paper